Systemic necrotizing vasculitis

W. L. Gross

doi:10.1016/S0950-3579(97)80046-5

Systemic necrotizing vasculitis

W. L. Gross^*

^*Corresponding author for this work

Clinic of Rheumatology

32 Citations (Scopus)

Abstract

The revival of interest in systemic necrotizing vasculitis was initiated by the discovery of its association with anti-neutrophil cytoplasmic antibodies (ANCA). The close association of certain ANCA subspecificities, for example, proteinase 3 (Pr3) and myeloperoxidase ANCA, with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome has led to their designation as 'ANCA-associated vasculitides'. This article describes the common and divergent clinical and immunological features of the members of this 'new' family of systemic necrotizing vasculitis, which continues to grow with the widespread use of ANCA testing. In addition, the 'standard' treatment for systemic necrotizing vasculitis (daily 'low dose' cyclophosphamide plus glucocorticosteroids or 'Fauci's scheme') is compared with new stage and activity adapted therapeutic regimens.

Original language	English
Journal	Bailliere's Clinical Rheumatology
Volume	11
Issue number	2
Pages (from-to)	259-284
Number of pages	26
ISSN	0950-3579
DOIs	https://doi.org/10.1016/S0950-3579(97)80046-5
Publication status	Published - 1997

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0950-3579(97)80046-5

Cite this

@article{66194230f82141bcacba5c80148a74d1,

title = "Systemic necrotizing vasculitis",

abstract = "The revival of interest in systemic necrotizing vasculitis was initiated by the discovery of its association with anti-neutrophil cytoplasmic antibodies (ANCA). The close association of certain ANCA subspecificities, for example, proteinase 3 (Pr3) and myeloperoxidase ANCA, with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome has led to their designation as 'ANCA-associated vasculitides'. This article describes the common and divergent clinical and immunological features of the members of this 'new' family of systemic necrotizing vasculitis, which continues to grow with the widespread use of ANCA testing. In addition, the 'standard' treatment for systemic necrotizing vasculitis (daily 'low dose' cyclophosphamide plus glucocorticosteroids or 'Fauci's scheme') is compared with new stage and activity adapted therapeutic regimens.",

author = "Gross, {W. L.}",

year = "1997",

doi = "10.1016/S0950-3579(97)80046-5",

language = "English",

volume = "11",

pages = "259--284",

journal = "Bailliere's Clinical Rheumatology",

issn = "0950-3579",

number = "2",

}

TY - JOUR

T1 - Systemic necrotizing vasculitis

AU - Gross, W. L.

PY - 1997

Y1 - 1997

N2 - The revival of interest in systemic necrotizing vasculitis was initiated by the discovery of its association with anti-neutrophil cytoplasmic antibodies (ANCA). The close association of certain ANCA subspecificities, for example, proteinase 3 (Pr3) and myeloperoxidase ANCA, with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome has led to their designation as 'ANCA-associated vasculitides'. This article describes the common and divergent clinical and immunological features of the members of this 'new' family of systemic necrotizing vasculitis, which continues to grow with the widespread use of ANCA testing. In addition, the 'standard' treatment for systemic necrotizing vasculitis (daily 'low dose' cyclophosphamide plus glucocorticosteroids or 'Fauci's scheme') is compared with new stage and activity adapted therapeutic regimens.

AB - The revival of interest in systemic necrotizing vasculitis was initiated by the discovery of its association with anti-neutrophil cytoplasmic antibodies (ANCA). The close association of certain ANCA subspecificities, for example, proteinase 3 (Pr3) and myeloperoxidase ANCA, with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome has led to their designation as 'ANCA-associated vasculitides'. This article describes the common and divergent clinical and immunological features of the members of this 'new' family of systemic necrotizing vasculitis, which continues to grow with the widespread use of ANCA testing. In addition, the 'standard' treatment for systemic necrotizing vasculitis (daily 'low dose' cyclophosphamide plus glucocorticosteroids or 'Fauci's scheme') is compared with new stage and activity adapted therapeutic regimens.

UR - http://www.scopus.com/inward/record.url?scp=0030805817&partnerID=8YFLogxK

U2 - 10.1016/S0950-3579(97)80046-5

DO - 10.1016/S0950-3579(97)80046-5

M3 - Journal articles

C2 - 9220078

AN - SCOPUS:0030805817

SN - 0950-3579

VL - 11

SP - 259

EP - 284

JO - Bailliere's Clinical Rheumatology

JF - Bailliere's Clinical Rheumatology

IS - 2

ER -

Systemic necrotizing vasculitis

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this